[go: up one dir, main page]

BRPI0820406A2 - Methods to identify increased nmda receptor antagonists - Google Patents

Methods to identify increased nmda receptor antagonists

Info

Publication number
BRPI0820406A2
BRPI0820406A2 BRPI0820406-3A BRPI0820406A BRPI0820406A2 BR PI0820406 A2 BRPI0820406 A2 BR PI0820406A2 BR PI0820406 A BRPI0820406 A BR PI0820406A BR PI0820406 A2 BRPI0820406 A2 BR PI0820406A2
Authority
BR
Brazil
Prior art keywords
methods
receptor antagonists
nmda receptor
identify increased
increased nmda
Prior art date
Application number
BRPI0820406-3A
Other languages
Portuguese (pt)
Inventor
Raymond J Dingledine
Stephen F Traynelis
Dennis C Liotta
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of BRPI0820406A2 publication Critical patent/BRPI0820406A2/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2842Pain, e.g. neuropathic pain, psychogenic pain
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2857Seizure disorders; Epilepsy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2871Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0820406-3A 2007-11-06 2008-11-06 Methods to identify increased nmda receptor antagonists BRPI0820406A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98592407P 2007-11-06 2007-11-06
US98592207P 2007-11-06 2007-11-06
PCT/US2008/082660 WO2009061935A2 (en) 2007-11-06 2008-11-06 Methods of identifying safe nmda receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0820406A2 true BRPI0820406A2 (en) 2015-05-19

Family

ID=40626437

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820406-3A BRPI0820406A2 (en) 2007-11-06 2008-11-06 Methods to identify increased nmda receptor antagonists

Country Status (12)

Country Link
EP (1) EP2212694A4 (en)
JP (1) JP2011503013A (en)
KR (1) KR20100100858A (en)
CN (1) CN101918832A (en)
AU (1) AU2008323877A1 (en)
BR (1) BRPI0820406A2 (en)
CA (1) CA2704475A1 (en)
EA (1) EA201070571A1 (en)
IL (1) IL205432A0 (en)
MX (1) MX2010004971A (en)
WO (1) WO2009061935A2 (en)
ZA (1) ZA201003724B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014159960A (en) * 2011-06-08 2014-09-04 Astellas Pharma Inc Automatic measurement method for spontaneous pain action of chronic pain model animal
SG10202007661XA (en) * 2015-05-22 2020-09-29 Vistagen Therapeutics Inc Therapeutic uses of l-4-chlorokynurenine
US10583171B2 (en) 2015-11-30 2020-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale) NMDAR antagonists for the treatment of diseases associated with angiogenesis
CN111960514A (en) * 2020-08-28 2020-11-20 浙江浙能技术研究院有限公司 A kind of electrodialysis intelligent control system and method for desulfurization wastewater concentration
EP4395783A4 (en) 2021-09-02 2025-11-26 Univ Emory Selective antagonists of the N-methyl-D-aspartate receptors of the GLUN2B subunit with increased potency at acidic pH

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072542A2 (en) * 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
KR20030063765A (en) * 2002-01-24 2003-07-31 엘지전자 주식회사 Objective Lens for Pick Up System
UY27939A1 (en) * 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
CN1894279A (en) * 2003-12-16 2007-01-10 安万特药物公司 secreted inhibitor of neuroapoptosis protein
WO2006023957A1 (en) * 2004-08-23 2006-03-02 Emory University Improved selection of-ph dependent compounds for in vivo therapy

Also Published As

Publication number Publication date
CA2704475A1 (en) 2009-05-14
EA201070571A1 (en) 2010-12-30
JP2011503013A (en) 2011-01-27
MX2010004971A (en) 2010-07-28
KR20100100858A (en) 2010-09-15
EP2212694A4 (en) 2011-10-12
EP2212694A2 (en) 2010-08-04
WO2009061935A3 (en) 2009-08-20
CN101918832A (en) 2010-12-15
AU2008323877A1 (en) 2009-05-14
WO2009061935A2 (en) 2009-05-14
IL205432A0 (en) 2010-12-30
ZA201003724B (en) 2013-10-30

Similar Documents

Publication Publication Date Title
LTPA2020513I1 (en) S1P receptor agonist dosing
BRPI0913930A2 (en) prostaglandin d2 receptor antagonists
BRPI0910118A2 (en) glucagon receptor antagonists
EP2150115A4 (en) RECEPTOR ANTAGONISTS OF CYCLOPROPYLPYRROLIDINE OREXINE
DK2821407T3 (en) PIPERIDINONCARBOXAMIDAZAINDAN-CGRP RECEPTOR ANTAGONISTS
ATE524460T1 (en) PYRIDONE-GPR119-G PROTEIN-COUPLED RECEPTOR AGONISTS
EP2150167A4 (en) SEMI-DISPOSABLE ENDOSKOP
DK2252581T3 (en) CAPE-SELECTIVE OPIOID RECEPTOR ANTAGONIST
EP2350060A4 (en) MELANOCORTIN RECEPTOR ANTAGONISTS
BRPI0820447A2 (en) Glucocorticoid Receptor Agonists
EP1981902A4 (en) NOGO RECEPTOR ANTAGONISTS
BRPI0907364A2 (en) N, n-disubstituted aminoalkylbiphenyl prostaglandin d2 receptor antagonists
BRPI0910592A2 (en) somatostatin receptor 2 antagonists
HRP20170246T1 (en) DOSAGE MODE FOR SELECTIVE S1P1-RECEPTOR AGONIST
BRPI0912362A2 (en) nmda receptor antagonist for the treatment of neuropsychiatric disorders
BRPI0810926A2 (en) CRIG ANTAGONIST
DK2443104T3 (en) DISUBSTITUTED PHTHALAZINE-HEDGEHOG-STI ANTAGONISTS
EP2490709A4 (en) GLP-2 RECEPTOR AGONISTS
BRPI0920440A2 (en) alkylation feed preparation
BRPI0811509A2 (en) MOUSE
EP2160579A4 (en) CALORIMETER
BR112012003701A2 (en) "new quinoline-hepcidin antagonists"
BRPI0918004A2 (en) glucagon antagonists
DK2364185T3 (en) DISUBSTITUTED PHTHALAZINE-HEDGEHOG PATHWAY ANTAGONISTS
HUE037394T2 (en) Clever-1 receptor antagonists to block immune-type 2 macrophages

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.